Blood Res 2019; 54(2): 153-156
What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness
Naohiro Sekiguchi1,2, Airi Hamano3, Tomoko Kitagawa2, Kenichi Ito1, Kazuhiko Hirano4, Kazuaki Yamada4
1Hematology Division, 2Clinical Research Division, 3Pharmaceutical Division, 4Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan
Correspondence to: Naohiro Sekiguchi
Hematology Division, National Hospital Organization Disaster Medical Center, 3256 Midori-cho, Tachikawa, Tokyo 190-0014, Japan
Received: January 31, 2019; Revised: February 25, 2019; Accepted: March 8, 2019; Published online: June 30, 2019.
© The Korean Journal of Hematology. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


This Article

Current Issue


Indexed/Covered by

Today : 51  /
Total : 147,756